Cover Image
市場調查報告書

生長激素缺乏症 (GHD) - 到2024年的流行病學預測

EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026

出版商 GlobalData 商品編碼 338804
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
生長激素缺乏症 (GHD) - 到2024年的流行病學預測 EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026
出版日期: 2017年06月01日 內容資訊: 英文 36 Pages
簡介

生長激素缺乏症 (GHD) ,是特徵為生長激素低或分泌不足的內分泌障礙。在全球主要7個國家(美國、法國、德國、義大利、西班牙、英國、日本)生長激素缺乏症 (GHD) 和確診的發病數量,預計從2014年的97,985件,到2024年達100,494件,增加0.26%。

本報告提供全球主要7個國家的生長激素缺乏症 (GHD) 調查分析、疾病的背景、危險因素和共生病症、全球趨勢、流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • GHD的流行病學預測
    • 確診的發病數量
    • 確診的發病數量:性別
    • 確診的發病數量:各年齡
    • 確診的年齡調整罹患率
    • 確診的發病數量 (兒童) :各病因性分類
    • 確診的發病數量 (成人) :各病因性分類
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

GHD is an endocrine disorder characterized by the insufficient production of GH by the pituitary gland (CGF, 2003). The ICD-10 Clinical Modification (ICD-10-CM) code for GHD is E23.0. GHD is more commonly seen in children, although it can develop during adulthood. GHD can be present from birth, in which case it is known as congenital, or it can be secondary due to brain trauma and is known as acquired. The signs and symptoms of the disease can vary. Generally, a child with GHD is born with normal size at birth, but has delayed rates of bone development and bone lengthening later on. GHD in children affects growth and development.

In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes will increase from 109,551 cases in 2016 to 112,450 cases in 2026 at an Annual Growth Rate (AGR) of 0.26%. Our epidemiologists forecast an increase in the diagnosed prevalent cases of GHD in all markets except Germany and Japan.

In 2016, the US made up about 48% of all diagnosed prevalent cases of GHD in the 7MM. In 2016, the 5EU made up approximately 40%, and Japan made up nearly 13%, of all cases of GHD in the 7MM. Our epidemiologists maintained a consistent forecast methodology across all the 7MM, which allows for comparison between each of the seven markets. Due to the limited availability of market-specific epidemiological studies available, further research is needed to better understand inter-market variations of the epidemiological parameters.

The report "EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026" provides an overview of the risk factors, comorbidities, and global trends for GHD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of GHD in children (ages 18 years and younger) and adults (ages 19 years and older) segmented by age and sex from 2016 to 2026. The diagnosed prevalent cases of GHD are further segmented into the classification of the disease (idiopathic and organic in children, and idiopathic and acquired in adults). Organic GHD in children is further segmented into congenital and acquired. GHD in adults is segmented by timing of disease onset: childhood onset GHD (COGHD) and adult onset GHD (AOGHD).

Scope

  • The Growth Hormone Deficiency (GHD) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of GHD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of GHD in children (ages 18 years and younger) and adults (ages 19 years and older) segmented by age and sex. The diagnosed prevalent cases of GHD are further segmented into the classification of the disease (idiopathic and organic in children, and idiopathic and acquired in adults). Organic GHD in children is further segmented into congenital and acquired. GHD in adults is segmented by timing of disease onset: childhood onset GHD and adult onset GHD.
  • The GHD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The GHD EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global GHD market.
  • Quantify patient populations in the global GHD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GHD therapeutics in each of the markets covered.
  • Identify the percentage of GHD diagnosed prevalent cases by various clinical segmentations.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Executive Summary 4

  • 2.1 Related Reports 5
  • 2.2 Upcoming Reports 6

3 Epidemiology 7

  • 3.1 Disease Background 7
  • 3.2 Risk Factors and Comorbidities 8
  • 3.3 Global and Historical Trends 9
    • 3.3.1 GHD in children 10
    • 3.3.2 GHD in adults 11
  • 3.4 Forecast Methodology 11
    • 3.4.1 Sources 13
    • 3.4.2 Forecast Assumptions and Methods 16
  • 3.5 Epidemiological Forecast for GHD (2016-2026) 22
    • 3.5.1 Diagnosed Prevalent Cases of GHD 22
    • 3.5.2 Age-Specific Diagnosed Prevalent Cases of GHD 23
    • 3.5.3 Sex-Specific Diagnosed Prevalent Cases of GHD 24
    • 3.5.4 Idiopathic and Organic GHD in Children 25
    • 3.5.5 Congenital and Acquired GHD Out of Organic GHD in Children 26
    • 3.5.6 Idiopathic and Acquired GHD in Adults 27
    • 3.5.7 Onset Timing 28
  • 3.6 Discussion 29
    • 3.6.1 Epidemiological Forecast Insight 29
    • 3.6.2 Limitations of Analysis 30
    • 3.6.3 Strengths of the Analysis 30

4 Appendix 31

  • 4.1 Bibliography 31
  • 4.2 About the Authors 34
    • 4.2.1 Epidemiologist 34
    • 4.2.2 Reviewers 34
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 35
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 35
  • 4.3 About GlobalData 36
  • 4.4 Contact Us 36
  • 4.5 Disclaimer 36

List of Tables

1.1 List of Tables

  • Table 1: Risk Factors and Comorbidities for GHD 8
  • Table 2: Diagnosed Prevalent Cases of GHD, Men and Women, All Ages, for 2016-2026. 22

List of Figures

1.2 List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of GHD, Both Sexes, All Ages, 2016 and 2026 5
  • Figure 2: Age-Standardized Diagnosed Prevalence of GHD, Men and Women, All Ages, 2016 10
  • Figure 3: Case Flow Map of GHD 12
  • Figure 4: Sources Used an
Back to Top